# P&T Committee Meeting Minutes

**Subject:** Louisiana Department of Health and Hospitals
Medicaid Pharmaceutical and Therapeutic Committee Meeting

**Location:**
- 628 North Fourth Street
- Baton Rouge, LA
- Bienville Building
- Room 118

**Date:** May 4, 2016

**Members Present:**
- Brian Boulmay, MD
- Jill Comeau, PharmD
- Jeff Deyo, MD
- Martha Harris, PharmD
- James Hussey, MD
- James Lu, MD
- Ed Mader, MD
- Katherine McDonald, MD
- Mary R. McKay, RPh
- Ben Orlando, RPh
- Suki Subbiah, MD

**DHH Pharmacy Program Staff Present:**
- Melwyn Wendt, RPh
- Germaine Becks-Moody, PhD, BHFS Program Manager
- Sue Fontenot, RPh
- Paul Knoche, RPh
- Kim Sullivan
- Mary Wolfe

**Contractors Present:**
- Nina Bandali, PharmD, Magellan Medicaid Administration
- Gabrielle Johnson-Stewart, University of Louisiana at Monroe (ULM)
- Jennifer Pickett, Certified Court Reporter

**Others Present:**
Presenters are listed in the minutes and sign in sheets and others in attendance from DHH, Bureau of Health Services Financing, Pharmacy Benefits Section upon request.

---

**Call to Order**

Marty R. McKay, Chairman, called the meeting to order at 9:16 a.m.
Parliamentary Business

A. Introduction of Members/Roll Call. Committee members and staff introduce themselves.

B. Approval of Minutes. Mr. McKay asked for a motion to approve the minutes from October 28, 2015. There were no objections to approving the minutes. Mr. McKay asked for a motion to reorder the sequence of the agenda.

Reports
Ms. Wendt stated that there are three additional reports in the packets provided to members. She reminded everyone that, in November of 2012, pharmacy was carved into managed care with about 50% of recipients. In February of 2015, approximately an additional 35% moved into managed care; therefore, about 85% of recipients are in managed right now. This is the explanation for the numbers on the prior authorization report. The Preferred Drug List (PDL) is also included in the packet. This is the information voted at the October 2015 meeting and went into effect on January 1, 2016. Magellan is the administrator of the PDL and has provided a program overview with information on market shift and the top five classes impacted by PDL operations.

P&T Bylaws – Proposed Amendment
Ms. Sullivan stated that all members should have received the proposed changes to the P&T bylaws listed on page 4, Section 2. The change would be to eliminate the requirement about Wednesday meetings. Dr. McDonald motioned to strike Section 2, and Mr. Orlando seconded it. Dr. Mader asked if the change was to the day or the specific week. Mr. McKay responded that the decision would be at the discretion of the Chair after polling the members to ensure a better chance for a quorum. Dr. Dego suggested that advanced notification be provided. A roll call vote was taken with all in favor.

Ethics Reminder
Ms. Sullivan reminded all that P&T Committee members are deemed state employees and must comply with the Code of Governmental Ethics. She suggested that Committee members go to the Board of Ethics website for a webinar training. If anyone has personal ethical questions or issues, Ms. Sullivan offered her email address, Kimberly.sullivan@ia.gov. The website also provides prior ethics opinions about the P&T Committee and P&T Committee members.

New Business

A. Therapeutic Class Reviews of Spring Drug Classes/Drug Manufacturer Testimony
   In accordance with state law and the P&T Committee’s bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee’s review.

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Representing</th>
<th>Drug/Issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunil Majethia</td>
<td>Gilead Sciences</td>
<td>Harvoni</td>
</tr>
<tr>
<td>Laura Hill</td>
<td>Abbvie</td>
<td>Viekira Pak, Technivie</td>
</tr>
<tr>
<td>Ashlie Singletary</td>
<td>Merck</td>
<td>Zepatier</td>
</tr>
<tr>
<td>---------------------</td>
<td>-------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Peter Ishak</td>
<td>Daiichi Sankyo</td>
<td>Savaysa</td>
</tr>
<tr>
<td>Christine Dube</td>
<td>AstraZeneca</td>
<td>Movantik</td>
</tr>
<tr>
<td>Christopher Kant</td>
<td>Allergan</td>
<td>Viberzi</td>
</tr>
<tr>
<td>Jeri Ann Godowski</td>
<td>NovoNordisk</td>
<td>Trosiba</td>
</tr>
<tr>
<td>Brent Day</td>
<td>Biogen Idec</td>
<td>Tecfidera</td>
</tr>
<tr>
<td>Julia Compton</td>
<td>Novartis</td>
<td>Gilenya</td>
</tr>
<tr>
<td>Rose Mullen</td>
<td>Alkermes</td>
<td>Vivitrul</td>
</tr>
<tr>
<td>Greg Kitchens</td>
<td>Actelion</td>
<td>Uptravi</td>
</tr>
<tr>
<td>Kirsten Mar</td>
<td>AstraZeneca</td>
<td>Brilinta</td>
</tr>
<tr>
<td>Ashlie Singletary</td>
<td>Merck</td>
<td>Zontivity</td>
</tr>
</tbody>
</table>

**NOTE**: Names of speakers who were present and yielded their time back were not captured.

**Hepatitis C Agents**

Mr. McKay stated that he will reorder the agenda and discuss the Hepatitis C Agents first and then continue with the rest of the agenda. Dr. Deyo made the motion to accept. Dr. Mader seconded the motion. After discussion, there was no objection to the motion.

*Committee recommendations for the PDL are:*

- Daklinza
- Harvoni
- Pegasys Proclick
- Pegasys Syringe
- Pegasys Vial
- Ribavirin tablet
- Sovaldi
- Technivie
- Viekira Pak

**Analgesics Narcotics, Long**

Mr. Orlando made the motion to amend the recommendation. Dr. Comeau seconded the motion. After discussion, there was no objection to the motion.

*Committee recommendations for the PDL are:*

---

*MagellanRx*  
*Management*
- Fentanyl transderm
- Morphine ER tablet

**Analgesics Narcotics, Short**

Mr. Orlando made the motion to accept. Dr. McDonald seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- Apap/Codeine elixir, tablet
- Butalbital/caffeine/apap w/codeine
- Hydrocodone/apap solution/tablet
- Hydrocodone/ibuprofen
- Hydromorphone tablet
- Morphine IR tablet
- Morphine solution
- Oxycodone/apap tablet
- Oxycodone solution
- Oxycodone tablet
- Tramadol
- Tramadol/apap

**Angiotensin Modulator Combinations**

Mr. Orlando made the motion to accept. Dr. Mader seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- Amlodipine/benazepril
- Amlodipine/valsartan
- Amlodipine/valsartan/HCTZ
**Angiotensin Modulators**

Dr. McDonald made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- Benazepril
- Enalapril
- Enalapril/HCTZ
- Entresto
- Irbesartan
- Irbesartan/HCTZ
- Lisinopril
- Lisinopril/HCTZ
- Losartan
- Losartan/HCTZ
- Ramipril
- Valsartan
- Valsartan/HCTZ

**Antibiotics, GI**

Mr. Orlando made the motion to accept. Dr. Mader seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- Metronidazole tablet
- Neomycin
- Vancocin

**Antibiotics, Inhaled**

Mr. Orlando made the motion to accept. Dr. McDonald seconded the motion. There was no objection to the motion.
Committee recommendations for the PDL are:

- Bethksis
- Kitabiis Pak

**Antibiotics, Topical**

Mr. Orlando made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Mupirocin ointment

**Antibiotics, Vaginal**

Mr. Orlando made the motion to accept. Dr. Hussey seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Clindamycin
- Metronidazole

**Anticoagulants**

Dr. Mader made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Eliquis
- Fragmin vial
- Lovenox syringe, vial
- Pradaxa
- Warfarin
- Xarelto
- Xarelto dose pack

**Antivertigo/Antiemetic Agents**

Mr. Orlando made the motion to accept. Dr. Mader seconded the motion. There was no objection to the motion.
Committee recommendations for the PDL are:

- Emend
- Meclizine
- Metoclopramide solution, syringe, tablet, vial
- Ondansetron disp syringe, ODT, solution, tablets, vial
- Phenergan ampule, vial
- Prochlorperazine injection, oral, rectal
- Promethazine ampule, rectal, syrup, tablet, vial
- Transderm-scop
- Trimethobenzamide

Antifungals, Oral

Mr. Orlando made the motion to accept. Dr. Harris seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Clotrimazole mucous membrane
- Fluconazole suspension, tablet
- Griseofulvin suspension
- Griseofulvin ultramicrosize
- Nystatin suspension, tablet
- Terbinafine

Antifungals, Topical

Mr. Orlando made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:
- Clotrimazole cream, solution Rx
- Clotrimazole-betamethasone cream
- Ketoconazole cream, shampoo
- Nystatin cream, ointment, powder
- Nystatin-triamcinolone cream, ointment

**Antimigraine Agents, Triptans**

Dr. McDonald made the motion to accept. Dr. Mader seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- Imitrex kit, nasal spray, vial
- Rizatriptan ODT, tablet
- Sumatriptan tablet

**Antiparasitics, Topical**

Mr. Orlando made the motion to accept. Dr. Deyo seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- Natroba
- Permethrin cream
- Sklice
- Ulesfia

**Antivirals, Oral – New class**

Mr. Orlando made the motion to accept. Dr. Hussey seconded the motion. After discussion, there was no objection to the motion.

*Committee recommendations for the PDL are:*

[Signature]

11/2/16